Palmitoylethanolamide: lowers doses of morphine, oxycodon and other opiates needed

The development of palmitoylethanolamide, an endogenous fatty acid amide, as an FDA-approved prescription drug in the USA has started by a small company, Prismic. This is a result of recent data confirming that palmitoylethanolamide demonstrate a clinical “entourage” or synergistic effect when administered in combination or concomitantly with certain analgesics such as THC, oxycodone, morphine, and other opiates.

This has a clear clinical benefit in that lower doses of the analgesic drugs are required to achieve the desired therapeutic effect. Thus the risk on classical opioid adverse events is reduced, as well as the risk of dependency and tolerance.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: